Bayer AG
BAYN: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€97.00 | Pwkscz | Crnkl |
Bayer's Wide Portfolio of Drug and Crop Science Products Should Enable Steady Long-Term Cash Flows
Business Strategy and Outlook
Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a wide economic moat. Also, the past divestiture of no-moat material science group Covestro leaves the company in a stronger competitive position.